Assessment methodology of pathomorphological regression of melanoma metastasis in the sentinel lymph node after neoadjuvant/perioperative immunotherapy
Authors:
- L.V. MoskvinaLML.V. Moskvina
- G.A. RaskinGRG.A. Raskin
- N.A. SavelovNSN.A. Savelov
- Ya.V. VishnevskayaYVYa.V. Vishnevskaya
- L.E. ZavalishinaLZL.E. Zavalishina
- D.O. ZagvozkinaDZD.O. Zagvozkina
- A.G. KudaibergenovaAKA.G. Kudaibergenova
- D.A. TsekatunovDTD.A. Tsekatunov
- O.YU. ChukhrayOCO.YU. Chukhray
- A.YU. ShamanovaASA.YU. Shamanova
- I.V. ShapozhnikovaISI.V. Shapozhnikova
- K.V. ShelekhovaKSK.V. Shelekhova
- 18 June 2026
- journal article
- abstracts
- Published by Media Sphere Publishing Group in Russian Journal of Archive of Pathology
- Vol. 88 (3) , 79-84
Abstract
This methodology has been developed to standardize the pathology evaluation of melanoma metastasis regression in the sentinel lymph node after neoadjuvant/perioperative immunotherapy in patients with stage III resectable cutaneous melanoma. The methodology is intended for use by pathologists, clinical and surgical oncologists, and healthcare quality assessment experts. It can be implemented as a local protocol for pathological examination, as well as integrated into national clinical guidelines and relevant organizational and methodological documents.Keywords
This publication has 6 references indexed in Scilit:
- Меланома кожиMalignant tumours, 2025
- Updated pan-tumor guidelines for neoadjuvant scoring of pathologic response: a joint SITC and INMC effortAnnals of Oncology, 2025
- Pathological response calculation assessment remains accurate with reduced tumor bed examination after neoadjuvant immunotherapy in clinically detectable stage III melanomaAnnals of Oncology, 2025
- Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trialNature Medicine, 2022
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)Nature Medicine, 2021
- Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanomaAnnals of Oncology, 2018